

# Index

## A

Adeno-associated virus (AAV), 9  
Antisense oligonucleotides (AOs), 12

## B

Biologics License Application (BLA), 32  
Body mass index (BMI), 230  
Branched-chain amino acids (BCAA), 246

## C

Centronuclear myopathy (CNM), 313  
Chemistry, manufacturing, and controls (CMC)  
  aseptic processing, 174  
  chemical entity, 166  
  clinical suitability, 167  
  comprehensive and systematic  
    evaluation, 173  
  equipment, 176–177  
  excipients, 172  
    antibiotics, 170  
    combination therapy, 172  
    cryoprotective agents, 171  
    DMSO, 171  
    HSA, 171–172  
    residual contaminants, 170  
  facilities, 174–175  
  packaging, labeling, and transport, 172  
  personnel conducting  
    batch records, 177  
    culture systems, 178  
    documentation, 177  
    enzymatic applications, 178  
    ex vivo gene modification and  
      irradiation, 179  
    features, 178  
    labeling, 180  
    packaging, 179, 180  
    process validations, 181  
    product formulation, 179  
    product life-cycle, 178  
    product shipping, 181  
    quarantined materials, 180  
    storage and handling, 181  
    tissue-based product, 177  
  preclinical and IND phases, 158  
  PSC (*see* Pluripotent stem cell (PSC)  
    platforms)  
  qualification and oversight  
    acceptance criteria, 169  
    certificates of analysis, 170  
    certificates of origin, 169, 170  
    cGMP, 168  
    federal regulations, 168  
    specifications, 169  
  quality assurance  
    adverse events, 194  
    clinical production, 192  
    document controls, 193, 194  
    non-conforming products, 194  
    product developers, 195, 196  
    product tracking, 195  
  quality control  
    adventitious agents, 185  
    biological products, 182  
    cellular contaminants, 186  
    endotoxin testing, 187, 188

## Chemistry, manufacturing, and controls (CMC)

- (*cont.*)
- identity testing, 183
- in-process testing, 191
- intermediate tests, 182
- mycoplasma, 184
- potency, 189
- product expiration, 191, 192
- pyrogen, 187, 188
- regulations, 182
- residual contamination, 187
- reviewing and approving test, 182
- stability, 189, 190
- sterility testing, 183
- tumorigenicity, 188
- USP test, 184
- regulations, 158
- sterile products, 174
- tabulation of reagents
  - animal products, 167
  - clinical-grade products, 168
  - geographical origin and physical nature, 167
  - human serum products, 168
  - source, safety, and performance, 168
  - traceability, 167
- 21 CFR 1271, 158
- Coenzyme-Q10 (CoQ10), 258
- Congenital fiber-type disproportion (CFTD)
  - clinical and pathological features, 55
  - clinical heterogeneity, 57
  - genetics, 55, 56
- Congenital myopathy
  - biomarkers, lack of, 57, 58
  - candidate gene approach, 60
  - causes, 40
  - centronuclear myopathies
    - clinical features, 53
    - genetics, 54, 55
    - pathological features, 54
- CFTD
  - clinical and pathological features, 55
  - genetics, 55, 56
  - clinical heterogeneity, 56, 57
- core myopathies
  - clinical features, 50, 51
  - genetics, 52, 53
  - pathological features, 51, 52
- homozygosity mapping, 59
- linkage mapping and positional cloning, 58, 59
- nemaline myopathies
  - clinical features, 47, 49
  - genetics, 49, 50

- pathological features, 49
- next-generation sequencing
  - automated Sanger methods, 60
  - clinical implications, 62
  - exons and splice sites, 61
  - gene panels, 62, 63
  - structural variation, 63, 64
- targeted therapies
  - gene/protein replacement, 70
  - loss-of-function, 70
  - Zebra fish models, 64
- undefined CM, 56

**D**

- Dietary reference intakes (DRIs), 232
- Double-knockout mouse (dKO), 88
- Dual-energy x-ray absorptiometry (DXA), 231
- Duchenne muscular dystrophy (DMD)
  - causes, 88
  - cell differentiation, 140, 141
  - cellular and molecular environment
    - fibers, 97
    - inflammatory genes, 99
    - metabolic/oxidative stress, 97, 99
    - RhoA levels, 100
    - skeletal muscle environment, 100, 101
  - clinical manifestations, 87, 88
  - constant degeneration and regeneration, 88
  - CoQ10, 258
  - definition, 282
  - degenerative skeletal muscle conditions, 86
  - diagnosis, 144
  - digestion dysfunction, 237
  - disease-associated abnormalities, 145
  - dKO, 88
  - drug-nutrient interaction, 263
    - ACE inhibitors, 265
    - beta-blockers, 265, 267
    - bisphosphonates, 266
    - concomitant food and drug intake, 266–267
    - CoQ10, 267
    - corticosteroids, 262
    - definition, 261
    - glucocorticoids (*see* Glucocorticoids)
    - metformin, 264
    - pharmaceutical interactions, 261
    - pharmacodynamic interactions, 261
    - pharmacokinetic interactions, 261
    - risk, 262
  - drug screening
    - Dowling lab, 285
    - Hmox1, 287

- Kunkel lab, 285
  - large-scale chemical screens, 285
  - mdx* model, 287
  - PDE inhibitors, 286, 287
  - pharmacologic treatment, 285
  - phenotype, 285
  - serotonin and fluoxetine, 287
  - sildenafil citrate, 286
  - transcriptome analysis, 287
  - dystrophin deficiency, 87
    - biological functions, 133
    - cardiac death account, 130
    - extracellular calcium entry, 134, 135
    - gene encoding, 130
    - genetic mutations, 130
    - intracellular calcium release, 135
    - mdx* cardiomyocytes, 134
    - membrane barrier function, 133
    - mitochondria dysfunction, 136
    - nNOS-cGMP signaling, 136, 137
    - pathogenesis, 132
    - ROS production, 136
    - symptoms and management, 131, 132
  - energy and nutrient intakes, 234
  - esophageal and gastric dysfunction, 238
  - features, 145, 146
  - growth assessment
    - BMI, 230
    - height, 230
    - pubertal status, 231
    - weight, 230
  - idebenone, 259
  - inherited myopathies, 310–313
  - intestinal dysfunction, 238–239
  - iPSC application, 143, 144
  - neuromuscular disease, 226
  - nuclear reprogramming
    - cell fate conversion, 139, 140
    - induced pluripotency, 138
    - progeny cell identity, 137, 138
  - nutrient constituents/supplements
    - amino acids, 239
    - animal/human research, 239
    - arginine-butyrates, 248
    - BCAAs, 246
    - creatine, 249–251
    - glutamine, 249
    - GTE, 252–253
    - L-arginine, 246–247
    - L-carnitine, 252
    - NAC, 257–258
    - $\omega$ 3FA, 254–255
    - resveratrol, 256–257
    - taurine, 251–252
    - vitamin D, 239, 255–256
  - nutritional care, 228
  - nutritional issues
    - American cohort, 227
    - A Z-score, 227, 228
    - energy excess, 227
    - French cohort, 227
    - genetic mutations, 226
    - glucocorticosteroids, 227
    - isoforms, 226
    - striated and smooth activations, 227
    - weight, strength, and function, 228
  - overweight management, 236–237
  - pediatric nutrition and feeding, 231–232
  - pharmacological interventions, 282
  - phenotypes, 316
  - physical activity, 234–235
  - potency and toxicity, 144
  - REE, 234, 235
  - stem cell transplantation
    - acellular therapies, 97
    - CD133+ cells, 94
    - cell-based therapies, 97
    - ESCs, 95
    - induced pluripotent stem cells, 96
    - MDSC, 92
    - mesoangioblasts, 93, 94
    - MSCs, 95
    - myoendothelial and pericytes, 93
    - myogenic differentiation, 90
    - pluripotent cells, 90
    - progenitor cells, 89
    - satellite cells, 91
  - steroid therapy, 235–236
  - swallowing dysfunction, 237–238
  - telomeres, 88
  - underweight management, 237
  - urine-derived cells, 141, 142
  - weight management, 232
- E**
- Embryonic stem cells (ESCs), 96
- G**
- Glucocorticoids
    - calcium and vitamin D, 263
    - deflazacort and prednisone, 262
    - food effects, 263–264
  - Golden retriever muscular dystrophy (GRMD)
    - biomarkers
      - eccentric contractions, 317

## Golden retriever muscular dystrophy

- (GRMD) (*cont.*)
  - gait assessment, 320
  - pelvic limb, 317
  - respiratory assessment, 320
- cardiac disease, 315, 316
- DMD phenotypes, 316
- extrapolation, 314
- fulminant form, 316
- proof-of-concept efficacy, 315
- scrappy*, 316

## Good laboratory practices (GLPs), 163

## Good manufacturing practices (cGMPs), 22, 168

## Green tea extract (GTE), 252–253

**H**

## Human embryonic stem cells (hESCs), 3

## Human serum albumin (HSA), 171–172

**I**

## Induced pluripotent stem cells (iPSCs), 158

## Inherited myopathies

- biomedical model, 310
- canine models
  - GRMD (*see* Golden retriever muscular dystrophy (GRMD))
  - XLMTM (*see* X-linked myotubular myopathy (XLMTM) phenotype)
- centronuclear myopathy, 313
- DMD, 310–313
- dogs, 310
- genetic models, 310
- muscular dystrophies, 309

## Intraparenchymal microinjection

- injection cannula design, 119, 120
- in vivo graft tracking, 121, 122
- stabilization, 113
- targeting intraspinal sites, 120, 121

## Investigational New Drug Application (IND), 32

**M**

## Master cell bank (MCB), 164–165

## Mechanotransduction, 215

## Mesenchymal stem cells (MSCs), 95

## Metabolic equivalents (METs), 234–235

## MicroRNA (miRNA)

- diagnostic markers, 302
- dystrophin expression, 301
- muscle fibrosis, 299

## muscle regeneration

- biology function, 303
  - cellular processes and diseases, 303
  - differentiation, 298
  - myoblasts, 297
  - proliferation, 297, 298
  - satellite cells, 297
  - muscle-specific miRNAs, 296
  - non-muscle-specific miRNAs, 296
  - oxidative stress, 301
  - pri-miRNAs, 295
  - slow and fast twitch muscles, 299–301
  - therapeutic agents, 302
  - upregulated and downregulated, 296
- Muscle-derived stem cells (MDSC), 92
- Myotubular myopathy (MTM), 14

**N**

## N-acetyl cysteine (NAC), 257–258

## Neuromuscular electrical stimulation (NMES), 217

**O**Omega-3 fatty acids ( $\omega$ 3FA), 254–255

## Ornithine transcarbamylase (OTCD), 10

**P**

## Pluripotent stem cell (PSC) platforms

- allogenic cell sources
  - components, 161
  - donor testing, 161
  - eligibility, 162
  - genetic normality and sterility, 162
  - HCT/Ps, 161
  - pathogenic screening, 162
  - relevancy, 162
  - 21 CFR 50.20, 161
- autologous cell sources
  - benefits, 159
  - blood cells, 159
  - differentiation processes, 161
  - drugs, 160
  - FDA, 160
  - non-integrating Sendai viral vector, 160
  - regenerative medicine research, 159
  - Regenexx™ procedure, 160
  - STEMCCA method, 160
- biohazardous and medical waste, 159
- cell bank systems
  - GLP, 163
  - MCB, 164–165

- patient cell bank, 166
    - structure, 163
    - WCB, 165
  - cell mobilization and collection, 162–163
  - iPSCs, 158
  - safety concerns, 158
  - schematic representation, 172
  - Poly(lactic-co-glycolic acid) (PLGA), 212
  - Pseudo-obstruction, 238
- R**
- Recombinant adeno-associated viral (rAAV)
    - vector
      - assay design and development, 26
      - assay qualification, 26
      - BLA, 32
      - clinical trials, 28, 29
      - commercial product, 33, 34
      - design and identification, 21, 22
      - FDA programs, 33
      - IND, 31, 32
      - manufacturing
        - cGMPs, 22
        - downstream processing, 25
        - formulation, 26
        - process development, 25
        - reagents and materials, 23, 25
        - scale, 22, 23
        - upstream processing, 25
      - product sampling and testing, 26, 27
      - product specifications setting, 27
      - stability testing, 27
      - toxicology study, 27, 28
  - Regenerative medicine
    - acquired myopathy, 4
    - adult stem cells, 6
    - animal models, 14
    - biologic scaffolds
      - adipogenic/fibrogenic conversion, 210
      - ECM, 208
      - glycans, 209
      - limitations, 212
      - macrophage phenotype, 210
      - site-appropriate tissue, 210
      - skeletal muscle repair, 210–211
      - soft tissue repair, 209
      - stem cells, 213–214
    - cellular reprogramming, 7–9
    - congenital myopathies, 4–5
    - definition, 1
    - degenerative muscle diseases, 3
    - electrical stimulation, 216–217
    - embryonic stem cells, 7
    - engineered scaffolds
      - growth factors, 212
      - limitations, 212
      - PCL and polyurethanes, 212
      - PLGA, 212
      - polypropylene, 212
      - stem cells, 213–214
    - gene repair, 12–13
    - gene therapy
      - AAV vectors, 10
      - DMD, 10
      - orphan diseases, 9
      - OTCD, 10
      - SCID-X1, 10
      - single-gene diseases, 9
    - hESCs, 3
    - mechanical stimulation
      - clinical applications, 219–220
      - intercellular signaling pathways, 215
      - mechanotransduction, 215
      - preclinical models, 218–219
      - signal propagation, 216
      - stretching, 216
    - MTM, 14
    - muscle tissue regeneration, 205
    - muscular dystrophies, 5–6
    - organ transplantation, 2
    - rehabilitation, 206
    - stem cell transplantation
      - adult stem cells, 207
      - anchoring, 207
      - DMD, 207
      - flow cytometry, 208
      - growth factors, 207
      - limitations, 208
      - pluripotency, 207
      - XLMTM, 13, 14
  - Resting energy expenditure (REE), 234, 235
- S**
- Stem cell cassette (STEMCCA) method, 159, 160
- U**
- Ullrich congenital muscular dystrophy (UCMD)
    - Bethlem myopathy, 288, 289
    - definition, 282
    - pharmacological interventions, 282
- W**
- Working cell bank (WCB), 165

**X**

- X-linked myotubular myopathy (XLMTM)
  - phenotype, 13
  - clinical observations, 321
  - eccentric contractions, 322
  - gait assessment, 323
  - pelvic limb, 322
  - respiratory assessment, 322
  - systemic treatment, 324
- X-linked severe combined immunodeficiency (SCID-X1), 10

**Z**

- Zebrafish
  - advantages
  - drug treatments, 284

- embryos, 283
- mutant strains, 284
- phenotypes, 283
- skeletal muscle structure, 283
- stereotyped structural and movement, 284
- collagen VI myopathies, 288–289
- DMD (*see* Duchenne muscular dystrophy (DMD))
- genome-edited strains, 290
- human muscle diseases, 290
- preclinical drug testing, 289–290
- UCMD
  - Bethlem myopathy, 288, 289
  - definition, 282
  - pharmacological interventions, 282